Who are Pegvisomant/ Sandostatin LAR's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pegvisomant-sandostatin-lar.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Pegvisomant/ Sandostatin LAR — Competitive Intelligence Brief

Pegvisomant/ Sandostatin LAR (Pegvisomant/ Sandostatin LAR) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Growth hormone receptor antagonist (pegvisomant); somatostatin analog (octreotide LAR). Area: Endocrinology.

marketed Growth hormone receptor antagonist (pegvisomant); somatostatin analog (octreotide LAR) Growth hormone receptor (pegvisomant); somatostatin receptors, particularly SSTR2 and SSTR5 (octreotide) Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Pegvisomant/ Sandostatin LAR (Pegvisomant/ Sandostatin LAR) — Pfizer. Pegvisomant is a growth hormone receptor antagonist that blocks GH signaling, while Sandostatin LAR is a somatostatin analog that inhibits growth hormone secretion.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pegvisomant/ Sandostatin LAR TARGET	Pegvisomant/ Sandostatin LAR	Pfizer	marketed	Growth hormone receptor antagonist (pegvisomant); somatostatin analog (octreotide LAR)	Growth hormone receptor (pegvisomant); somatostatin receptors, particularly SSTR2 and SSTR5 (octreotide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Growth hormone receptor antagonist (pegvisomant); somatostatin analog (octreotide LAR) class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pegvisomant/ Sandostatin LAR — Competitive Intelligence Brief. https://druglandscape.com/ci/pegvisomant-sandostatin-lar. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab